BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 32861288)

  • 21. Cost-effectiveness analysis of KTE-X19 CAR T therapy versus real-world standard of care in patients with relapsed/refractory mantle cell lymphoma post BTKi in England.
    Petersohn S; Salles G; Wang M; Wu J; Wade SW; Simons CL; Bennison C; Siddiqi R; Peng W; Kloos I; Castaigne G; Hess G
    J Med Econ; 2022; 25(1):730-740. PubMed ID: 35611697
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytogenetic findings in blastoid mantle cell lymphoma.
    Khoury JD; Sen F; Abruzzo LV; Hayes K; Glassman A; Medeiros LJ
    Hum Pathol; 2003 Oct; 34(10):1022-9. PubMed ID: 14608536
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Central nervous system involvement by mantle cell lymphoma.
    McLaughlin N; Wang Y; Witzig T; Villasboas J; Habermann T; Inwards D; Bennani N; Thanarajasingam G; Nowakowski G; Porrata L; Thompson C; Micallef I; Johnston P; Ansell S; Paludo J
    Leuk Lymphoma; 2023 Feb; 64(2):371-377. PubMed ID: 36416595
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mantle Cell Lymphoma: the Role of Risk-Adapted Therapy and Treatment of Relapsed Disease.
    Tarockoff M; Gonzalez T; Ivanov S; Sandoval-Sus J
    Curr Oncol Rep; 2022 Oct; 24(10):1313-1326. PubMed ID: 35639332
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy.
    Eyre TA; Walter HS; Iyengar S; Follows G; Cross M; Fox CP; Hodson A; Coats J; Narat S; Morley N; Dyer MJS; Collins GP
    Haematologica; 2019 Feb; 104(2):e68-e71. PubMed ID: 30190341
    [No Abstract]   [Full Text] [Related]  

  • 26. Sequence analysis proves clonal identity in five patients with typical and blastoid mantle cell lymphoma.
    Yin CC; Medeiros LJ; Cromwell CC; Mehta AP; Lin P; Luthra R; Abruzzo LV
    Mod Pathol; 2007 Jan; 20(1):1-7. PubMed ID: 17057651
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mantle Cell Lymphoma Involving Skin: A Clinicopathologic Study of 37 Cases.
    Kim DH; Medeiros LJ; Aung PP; Young KH; Miranda RN; Ok CY
    Am J Surg Pathol; 2019 Oct; 43(10):1421-1428. PubMed ID: 31219818
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Therapeutic Synergy of Selinexor and Venetoclax in Mantle Cell Lymphoma Through Induction of DNA Damage and Perturbation of the DNA Damage Response.
    Yuan S; Zuo W; Liu T; Fu H
    Technol Cancer Res Treat; 2023; 22():15330338231208608. PubMed ID: 37880950
    [No Abstract]   [Full Text] [Related]  

  • 29. Diagnostically challenging immunophenotypic shift in mantle cell lymphoma following ibrutinib and venetoclax therapy.
    Leitinger EJ; Wright RM; Nelson N; Anderson MA; Juneja S
    Pathology; 2021 Dec; 53(7):926-929. PubMed ID: 33947523
    [No Abstract]   [Full Text] [Related]  

  • 30. Understanding resistance mechanisms to BTK and BCL2 inhibitors in mantle cell lymphoma: implications for design of clinical trials.
    Agarwal R; Dawson MA; Dreyling M; Tam CS
    Leuk Lymphoma; 2018 Dec; 59(12):2769-2781. PubMed ID: 29912596
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma.
    Gerson JN; Handorf E; Villa D; Gerrie AS; Chapani P; Li S; Medeiros LJ; Wang M; Cohen JB; Churnetski M; Hill BT; Sawalha Y; Hernandez-Ilizaliturri FJ; Kothari S; Vose JM; Bast M; Fenske T; Rao Gari SN; Maddocks KJ; Bond D; Bachanova V; Kolla B; Chavez J; Shah B; Lansigan F; Burns T; Donovan AM; Wagner-Johnston N; Messmer M; Mehta A; Anderson JK; Reddy N; Kovach AE; Landsburg DJ; Glenn M; Inwards DJ; Ristow K; Karmali R; Kaplan JB; Caimi PF; Rajguru S; Evens A; Klein A; Umyarova E; Pulluri B; Amengual JE; Lue JK; Diefenbach C; Fisher RI; Barta SK
    Blood Adv; 2023 Dec; 7(24):7393-7401. PubMed ID: 37874912
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Obinutuzumab and venetoclax induced complete remission in a patient with ibrutinib-resistant non-nodal leukemic mantle cell lymphoma.
    Zhou X; Steinhardt MJ; Düll J; Krummenast F; Danhof S; Meckel K; Nickel K; Grathwohl D; Leicht HB; Rosenwald A; Einsele H; Rasche L; Kortüm M
    Eur J Haematol; 2020 Apr; 104(4):352-355. PubMed ID: 31922303
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal
    Prukova D; Andera L; Nahacka Z; Karolova J; Svaton M; Klanova M; Havranek O; Soukup J; Svobodova K; Zemanova Z; Tuskova D; Pokorna E; Helman K; Forsterova K; Pacheco-Blanco M; Vockova P; Berkova A; Fronkova E; Trneny M; Klener P
    Clin Cancer Res; 2019 Jul; 25(14):4455-4465. PubMed ID: 31004002
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinicopathologic features, management and outcomes of blastoid variant of mantle cell lymphoma: a Nebraska Lymphoma Study Group Experience.
    Bhatt VR; Loberiza FR; Smith LM; Armitage JO; Greiner TC; Bast M; Lunning MA; Bierman PJ; Vose JM; Bociek RG
    Leuk Lymphoma; 2016; 57(6):1327-34. PubMed ID: 26377137
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CAR T-Cell therapy for the management of mantle cell lymphoma.
    Huang Z; Chavda VP; Bezbaruah R; Dhamne H; Yang DH; Zhao HB
    Mol Cancer; 2023 Mar; 22(1):67. PubMed ID: 37004047
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Blastoid Mantle Cell Lymphoma of the Palate: Report of a Rare Aggressive Entity and Review of the Literature.
    Georgaki M; Theofilou VI; Pettas E; Piperi E; Stoufi E; Panayiotidis P; Nikitakis NG
    Head Neck Pathol; 2022 Jun; 16(2):631-642. PubMed ID: 34716903
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma.
    Jiang VC; Liu Y; Jordan A; McIntosh J; Li Y; Che Y; Jessen KA; Lannutti BJ; Wang M
    J Hematol Oncol; 2021 Aug; 14(1):132. PubMed ID: 34454548
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Blastoid mantle cell lymphoma presenting as acute leukemia: a case report.
    Dongre A; Kanchankar N; Deshmukh M; Wasnik D; Dongre T
    Pan Afr Med J; 2021; 39():150. PubMed ID: 34527166
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Blastoid variant of mantle cell lymphoma: late progression from classical mantle cell lymphoma and quantitation of minimal residual disease.
    Pott C; Schrader C; Brüggemann M; Ritgen M; Harder L; Raff T; Tiemann M; Dreger P; Kneba M
    Eur J Haematol; 2005 Apr; 74(4):353-8. PubMed ID: 15777349
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Classical type and blastoid variant mantle cell lymphoma in the same lymph node: Histology and cytological findings from a touch imprint specimen.
    Nakatsuka SI; Nagatomo T; Nagano T; Goto T; Hashimoto K
    Diagn Cytopathol; 2017 Apr; 45(4):364-370. PubMed ID: 28140514
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.